MedTrace Logo

Brain Biomarker of Endogenous Analgesia in Patients With Chronic Knee Pain

NCT05003323 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-01-13

No results posted yet for this study

Summary

This case-control study in patients with knee osteoarthritis and pain-free control individuals aims to develop a brain biomarker of endogenous analgesia that may be used in subsequent clinical trials. Deficits in central nervous system (CNS) pain inhibition may contribute to chronic pain intensity, but quantitative sensory testing (QST) methods are limited. Incorporating brain imaging to assessments of CNS pain inhibition, by examining activity in relevant brain networks, would allow for an objective, physiologic measure of CNS pain inhibition. Preliminary data in pain-free volunteers implicate cortical activity measured with functional near-infrared spectroscopy (fNIRS) during CNS pain inhibition. Broadly, the investigators hypothesize that variability in CNS pain inhibition contributes to variability in clinical pain intensity.

Conditions

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Benedict Alter, MD, PhD · University of Pittsburgh

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2023-10-20
Completion
2023-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05003323 on ClinicalTrials.gov